Key Highlights

  • Earnings per share were USD 0.01 against an estimate of a USD 0.08 loss.
  • Net income was USD 2.47 million, compared with a net loss of USD 4.54 million.
  • Loss from operations was USD 4.48 million, compared with USD 2.49 million.
  • Cash and cash equivalents were USD 11.4 million at September 30, 2026.

AEON Biopharma (NYSE American:AEON) reported Net Income of USD 2.47 million for the third quarter of 2026, compared with a net loss of USD 4.54 million in the prior-year quarter. Basic and diluted net income per share attributable to common stockholders was USD 0.01, compared with a loss of USD 0.39, against an estimate of a USD 0.08 loss.

The result included a gain of USD 7.01 million from the change in Fair Value of warrants. The company reported no Revenue in either period.

Third Quarter Results

Selling, general and administrative expenses were USD 2.99 million, compared with USD 1.93 million, which the company's management discussion described as an increase of USD 1.1 million, or 55%. Research and Development expenses were USD 1.52 million, compared with USD 597 thousand. The change in fair value of contingent consideration was a Credit of USD 22 thousand, compared with a credit of USD 37 thousand.

Total operating costs and expenses were USD 4.48 million, compared with USD 2.49 million, and the loss from operations was USD 4.48 million, compared with USD 2.49 million. Weighted average shares of common stock outstanding were 89,957,587, compared with 11,634,946.

Other Income and Nine-Month Results

The change in fair value of convertible notes was a loss of USD 214 thousand, compared with a loss of USD 1.88 million, and other income, net, was USD 148 thousand. Total other income, net, was USD 6.95 million, compared with a loss of USD 2.05 million, and income before taxes was USD 2.47 million.

For the nine months ended September 30, 2026, the loss from operations was USD 16.34 million, compared with USD 7.29 million. Selling, general and administrative expenses were USD 9.88 million, and research and development expenses were USD 6.49 million. The company recorded a gain of USD 16.61 million on the change in fair value of warrants, compared with USD 85.95 million, a loss of USD 9.15 million on the change in fair value of convertible notes, and a loss of USD 1.74 million on a derivative liability. The net loss was USD 10.48 million, compared with USD 2.09 million, and net loss per share was USD 0.17, compared with USD 0.23.

Balance Sheet and Going Concern Disclosure

Cash and cash equivalents were USD 11.42 million at September 30, 2026, compared with USD 3.01 million at December 31, 2025. Total Assets were USD 14.13 million, compared with USD 5.56 million, and total current liabilities were USD 4.57 million, compared with USD 6.90 million. Total liabilities were USD 11.74 million, compared with USD 60.59 million.

Additional paid-in Capital was USD 483.67 million, and the accumulated Deficit was USD 481.30 million. The filing states that the company is developing ABP-450 and expects to incur losses and use cash in its operations for the foreseeable future, and it discloses substantial doubt about the company's ability to continue as a going concern and to meet its obligations as they become due within one year after the financial statements are issued.

AEON Biopharma Q3 2026 Earnings: Key Takeaways

AEON Biopharma reported third quarter 2026 net income of USD 2.47 million and a loss from operations of USD 4.48 million. Cash and cash equivalents were USD 11.42 million at September 30, 2026.